Once-A-Day Pill Effective In Treating Sleep Apnea Without CPAP, Clinical Trial Says
Medically reviewed by Drugs.com
via HealthDayWEDNESDAY, May 20, 2026 — Some people with sleep apnea might be able to shed their CPAP masks in favor of a once-nightly pill, a new study says.
The experimental pill, called AD109, helps treat sleep apnea by making a person’s airways resistant to collapse, researchers say.
In clinical trials, people taking the pill saw their breathing interruptions decrease by about 44% compared to almost 18% for those taking a placebo, researchers reported May 18 in the American Journal of Respiratory and Critical Care Medicine.
Importantly, nearly 18% achieved complete control over their sleep apnea, researchers said.
“These results provide encouraging evidence that targeting neuromuscular dysfunction can translate into meaningful clinical outcomes, aligning with our evolving understanding of the disease biology,” said lead researcher Dr. Patrick John Strollo, a sleep medicine physician at the University of Pittsburgh Medical Center.
Obstructive sleep apnea occurs when a person’s throat muscles relax and block the airway, leading to brief pauses on and off during sleep, according to Mayo Clinic.
Continuous positive airway pressure (CPAP) machines are the gold standard treatment for sleep apnea, but many patients find them intolerable, Strollo said. People must sleep with a mask strapped to their face, next to a machine that can be noisy.
This new pill could provide an alternative to CPAP, researchers said.
“In many other chronic diseases, such as cardiovascular disease, asthma or type 2 diabetes, it would be unthinkable for the majority of diagnosed patients to remain untreated or undertreated. Yet that remains the reality in OSA,” Strollo said in a news release.
“An oral pill that targets the underlying neuromuscular drivers of airway collapse during sleep could help address this gap and broaden the range of effective options for patients who remain untreated today,” he said.
The pill combines two medications, aroxybuytinin and atomoxetine, which together work to resist the tendency of airway muscles to relax during sleep, researchers said.
The new clinical trial involved 318 people with sleep apnea who were randomly chosen to take AD109, along with another 319 people provided a placebo.
Results showed that AD109 reduced sleep apnea severity among more than 40% of patients, and led to complete disease control in nearly 18%.
Patients also had fewer nightly drops in their blood oxygen levels, researchers found.
The drug’s most common side effects were dry mouth, nausea, insomnia and difficulty urinating. About 21% of patients stopped therapy due to side effects.
AD109 has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for expedited review. Its developer, Apnimed, has submitted a new drug application to the FDA.
Apnimed funded this clinical trial.
Sources
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-05-20 21:53
Read more
- What's Fueling The High U.S. Death Rate? It Might Not Be What You Think
- VR Training Helps Autistic People Navigate Police Encounters
- Pentagon Drops Flu Vaccine Requirement For U.S. Military
- Former Tobacco Executive Takes CDC Role
- Super Shoes Might Increase Risk Of Running Injuries, Study Says
- U.S. Adults Interested in, but Lack Knowledge About, Brain Health
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions